4.3 Editorial Material

Evidence Needed for Efficacy of Antidepressant Medications Among Patients With Rheumatoid Arthritis

期刊

ANNALS OF PHARMACOTHERAPY
卷 56, 期 9, 页码 1065-1075

出版社

SAGE PUBLICATIONS INC
DOI: 10.1177/10600280211062271

关键词

rheumatoid arthritis; neuropathy; depression; serotonin norepinephrine reuptake inhibitors; tricyclic antidepressants

资金

  1. Avatar Foundation
  2. Tabula Rasa Healthcare (TRHC)

向作者/读者索取更多资源

Antidepressants may have a role in treating patients with RA and associated conditions, but further research is needed to assess their efficacy and safety.
Patients with rheumatoid arthritis (RA) experience pain from inflammation, joint destruction, and neuropathy. Antidepressants may play a role among patients with RA and depression, fibromyalgia, or neuropathy to achieve desired outcomes. This commentary evaluated evidence for medications individually and identified important variables for future research. While we await the results of well-designed studies, a trial of duloxetine or milnacipran may be considered for patients with remnant pain and RA remission. Research is needed to evaluate the efficacy and safety of serotonin-norepinephrine reuptake inhibitors and tricyclic antidepressants in patients with RA and associated comorbid conditions.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据